Delivery Order SPE2DB22D2218-SPE2DB25FR3EQ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,913.51 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) with an ultimate completion date of August 12, 2025. The contract employs firm fixed-price pricing and carries no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $6,059.18 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed price delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, PA....
- The Defense Logistics Agency awarded a delivery order valued at $13,132.00 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place...
- The Defense Logistics Agency awarded a delivery order valued at $22,621.69 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $18,191.81 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a direct fulfillment of pharmaceutical supply needs for federal medical procurement. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $25,569.98 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets in quantities of 60 units. This firm fixed price delivery order, issued on July 30, 2025, is set to be completed by July 31, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this requirement from its...
- The Defense Logistics Agency awarded a delivery order valued at $60,140.57 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The contract requires performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside provisions applied to the award. This...
- The Defense Logistics Agency awarded a delivery order valued at $14,182.44 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $4,519.47 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xeljanz is a prescription immunosuppressant medication used to treat rheumatoid...
- The Defense Logistics Agency awarded a $9,112.43 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xeljanz 5 mg tablets (60-count units). This is a firm fixed-price contract with an ultimate completion date of September 5, 2025, and represents a non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations. This...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB25FR3EQDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,093.90 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order was issued on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was utilized for this award. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen Drug Corp leverages this prime IDC to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. The Xeljanz order supports DLA's medical supply chain requirements for this immunosuppressive medication used in treating inflammatory conditions within the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 8/18/25 |